Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06162286 | A Phase 3b Randomized, Double-blind, Multi-center Study to Compare the Safety and Efficacy of Omadacycline to Moxifloxacin for Treating Adult Subjects With CABP | PHASE3 | RECRUITING | 100 | — | — | Nov 17, 2023 | Nov 30, 2025 | Jun 14, 2024 | 40 | China |
| Arm | Type | Description |
|---|---|---|
| Moxifloxacin | ACTIVE_COMPARATOR | Moxifloxacin IV/PO |
| Omadacycline | EXPERIMENTAL | Omadacycline IV/PO |
| Name | Type | Description |
|---|---|---|
| Omadacycline | DRUG | Omadacycline IV/PO |
| Moxifloxacin | DRUG | Moxifloxacin IV/PO |
Inclusion Criteria: 1. Written and signed informed consent obtained before any protocol specific assessment is performed. 2. Male or female, ages 18 years or older. 3. Has at least 3 of the following symptoms: * Cough * Production of purulent sputum * Dyspnea (shortness of breath) * Ch...